

SPECIAL ARTICLE

Idiopathic pulmonary fibrosis in the era of antifibrotic therapy: Searching for new opportunities grounded in evidence



C. Robalo-Cordeiro^{a,*}, P. Campos^b, L. Carvalho^c, A. Borba^d, S. Clemente^e, S. Freitas^f, S. Furtado^e, J.M. Jesus^g, C. Leal^h, A. Marquesⁱ, N. Meloⁱ, C. Souto-Moura^j, S. Neves^k, V. Sousa^c, A. Santos^l, A. Moraisⁱ

^a Pulmonology Department, Coimbra University Hospital, Faculty of Medicine of Coimbra, Coimbra, Portugal

^b Imagiology Department, Santa Maria Hospital, Northern Lisbon Hospital Centre, Lisbon, Portugal

^c Pathology Department, Faculty of Medicine of the University of Coimbra, Coimbra, Portugal

^d Pulmonology Department, Santa Marta Hospital, Central Lisbon Hospital Centre, Lisbon, Portugal

^e Pulmonology Department, Beatriz Ângelo Hospital, Loures, Portugal

^f Pulmonology Department, Coimbra University Hospital Centre, Coimbra, Portugal

^g Radiology Department, São João Hospital Centre, Oporto, Portugal

^h Radiology Department, Santa Marta Hospital, Central Lisbon Hospital Centre, Lisbon, Portugal

ⁱ Pulmonology Department, São João Hospital Centre, Oporto, Portugal

^j Pathology Department, São João Hospital Centre, Faculty of Medicine of Porto University, Oporto, Portugal

^k Pulmonology Department, Vila Nova de Gaia/Espinho Hospital Centre, Vila Nova de Gaia, Portugal

^l Prime Focus, Lisbon, Portugal

Received 12 May 2017; accepted 29 May 2017

Available online 28 June 2017

KEYWORDS

Idiopathic pulmonary fibrosis;
Interstitial lung disease;
Nintedanib;
Pirfenidone

Abstract Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease that up to now has been associated with a poor prognosis. However, the results of the INPULSIS and ASCEND trials and the approval of nintedanib and pirfenidone have marked the beginning of a new era for IPF patients. Questions remain, however. Should these drugs be used earlier? What effect will they have on more severe disease? Will their effects last beyond the trial period? This manuscript is the outcome of a multidisciplinary meeting between pulmonology, radiology, and pathology clinicians on the use of antifibrotic agents in IPF. In our opinion, the existing data show that pirfenidone and nintedanib slow functional decline in early stages

* Corresponding author.

E-mail address: carlos.crobalo@gmail.com (C. Robalo-Cordeiro).

of disease. These drugs also appear to result in therapeutic benefits when administered to patients with advanced disease at diagnosis and maintain effective over time. The data also suggest that continuing antifibrotic therapy after disease progression may confer benefits, but more evidence is needed. Early diagnosis and treatment are crucial for reducing functional decline, slowing disease progression, and improving quality of life.

© 2017 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Idiopathic pulmonary fibrosis (IPF) is a progressive and deadly disease with a mean survival of 3–5 years from the time of diagnosis. It is more common in men, smokers, and people over 50 years old.^{1,2} The condition is characterized by dyspnea on exertion, non-productive cough, crackles on auscultation, and digital clubbing. It is diagnosed using a specific combination of radiologic and/or histopathological patterns of usual interstitial pneumonia (UIP) and exclusion of other known causes of UIP.^{1,3} General physicians must be able to recognize the symptoms of IPF to ensure the timely referral of suspected cases, and it is essential that these are then evaluated by a multidisciplinary team with experience in interstitial lung diseases to ensure an accurate diagnosis.^{1,4–8}

This manuscript is the outcome of a multidisciplinary meeting in which pulmonology, radiology, and pathology clinicians came together to debate topics related to the use of antifibrotic drugs in the treatment of IPF.

IPF treatment: a recent (r)evolution

IPF was initially considered to be a chronic inflammatory process and therefore early treatment strategies aimed to eliminate or suppress the inflammatory component. In 2000, the first international guidelines on IPF diagnosis and treatment recommended corticosteroids and immunosuppressive/cytotoxic agents (azathioprine or cyclophosphamide) as “standard treatment”, despite the weak evidence available.⁹ This targeting of inflammatory pathways, however, produced disappointing results.^{4,10–12}

Understanding of IPF pathobiology improved significantly following the publication of the 2000 IPF guidelines and it was proposed that the disease might be the result of an aberrant healing response to recurrent alveolar epithelial cell injury.^{13,14} Guidelines published in 2011 concluded there was insufficient evidence to continue to recommend corticosteroid and immunomodulatory agents as standard therapy for IPF.¹⁵ The results of the IFIGENIA study, a double-blind clinical trial designed to investigate the potential role of antioxidant pathways in IPF, were published in 2005. The trial, which compared prednisolone plus azathioprine with prednisolone plus azathioprine plus N-acetylcysteine (NAC), showed a significantly reduced decline in forced vital capacity (FVC) ($p=0.02$) and diffusion capacity of the lung for carbon monoxide (DLCO) ($p=0.003$) in patients treated with

NAC combined with prednisolone and azathioprine after 52 weeks.¹⁶ Although the trial had some methodological pitfalls, this triple therapy became the new standard treatment for IPF.

Around the same time, pirfenidone, an orally bioavailable synthetic compound with antifibrotic, anti-inflammatory, and antioxidant effects, was being studied in clinical trials in Japan.^{17,18} Although the exact mechanism of action of pirfenidone in IPF is not yet completely understood, its anti-inflammatory effects are believed to result from the suppression of tumor necrosis factor α (TNF- α), interleukin (IL)-6, IL-12, and IL-8,¹⁹ while its anti-fibrotic effect is thought to result primarily from inhibition of expression of transforming growth factor beta – a profibrotic cytokine – although other pathways have been suggested.²⁰ The first Japanese trial, a phase II, multicenter, randomized, double-blind trial, showed no significant treatment effect for pirfenidone on the primary endpoint, which was a change from baseline in the lowest oxygen saturation by pulse oximetry [SpO_2] during a 6-min exercise test. It did, however, show that the high-dose treatment (1800 mg/day) had a positive effect in reducing VC decline, a secondary endpoint, at 9 months.¹⁷ In addition, acute exacerbations were only observed in the placebo group during the same period. A subsequent multicenter, randomized, double-blind phase III clinical trial of 275 IPF patients randomly assigned to pirfenidone 1800 mg/day, pirfenidone 1200 mg/day, or placebo for 52 weeks, showed a significantly slower decline in FVC and better progression-free survival in the two pirfenidone groups compared with placebo.¹⁸ Based on the results of these two studies, pirfenidone was approved for IPF treatment by the Japanese authorities in 2008.

Meanwhile, pirfenidone was also being studied in Europe and in the United States of America (USA) in the CAPACITY trials.²¹ The placebo-controlled phase III trials, CAPACITY 004 and 006, showed contradictory results, and the primary endpoint of a significant reduction in FVC decline at week 72 was only met in study 004. However, the pooled analysis revealed a significant reduction in the mean decline of absolute and percent predicted FVC and the number of patients with an FVC decline $\geq 10\%$ at week 72 in the 2403 mg/day pirfenidone group.²¹ In relation to the secondary endpoints, the patients in the 2403 mg/day group also had longer progression-free survival and a lower rate of decline in mean 6-min walk distance (6MWD) than patients in the placebo group.²¹ The results of this pooled analysis led to the approval of pirfenidone for IPF treatment by the European Medicines Agency (EMA) in 2011, although they were

not sufficient to convince the US Food and Drug Administration (FDA).

Despite the approval of pirfenidone in Japan and Europe, the triple therapy persisted as the treatment regimen of choice in many countries until the results of the PANTHER study were published.¹¹ The PANTHER study was a randomized clinical trial with three arms: a triple therapy arm, an NAC arm, and a placebo arm. The triple therapy arm was stopped after a mean follow-up of 32 weeks because of higher mortality and hospitalization rates than in the other two groups.¹¹

Despite some initial controversy, this event marked the end of triple therapy. Moreover, on completion of the PANTHER study in 2014, no significant differences were detected between NAC and placebo for changes in FVC (primary endpoint) or for death rates or frequency of acute exacerbations (secondary endpoints).²² Recent publications describing a therapeutic effect for NAC in a subgroup of IPF patients expressing the *TOLLIP* gene polymorphism rs3750920²³ and a potential benefit of inhaled acetylcysteine,²⁴ have rekindled the discussion about the potential therapeutic role of NAC and antioxidants as a therapeutic group in IPF.

After the evaluation of the CAPACITY trials,¹⁹ the ASCEND trial, which included 555 patients from the USA, Europe, and Australia randomly assigned to receive 2403 mg/day of pirfenidone or placebo for 52 weeks showed that the treatment group had a significantly reduced absolute FVC decline, fewer patients with an FVC decline $\geq 10\%$, better progression-free survival (defined as the time to occurrence of a confirmed absolute decrease of ≥ 10 percentage points in percent predicted FVC, a confirmed decrease of ≥ 50 m in the 6MWD, or death), and fewer patients with a decrease of ≥ 50 m in the 6MWD.²⁵ Moreover, pooled data from the CAPACITY and ASCEND trials evidenced a reduction in both all-cause and IPF-related mortality after one year.²⁵ These results further supported the efficacy of pirfenidone in IPF and led to FDA approval in 2014.

In the same year, nintedanib also received FDA approval after the INPULSIS trials.²⁶ Nintedanib is a small molecule tyrosine kinase inhibitor that targets the receptors of platelet-derived growth factor, fibroblast growth factor, and vascular endothelial growth factor. Blockage of these receptors may inhibit downstream signaling cascades of fibroblasts and myofibroblasts, attenuating the development of aberrant fibrosis.²⁷

In the phase II nintedanib trial TOMORROW, which included 432 IPF patients randomized to one of four doses of nintedanib (50 mg od, 50 mg bid, 100 mg bid, and 150 mg bid) or placebo, a significant reduction in FVC decline after 52 weeks was seen in the 150 mg bid group compared with placebo.²⁸ This subgroup of patients also had significantly fewer acute exacerbations and a smaller mean decrease in the St. George's Respiratory Questionnaire score. Two subsequent large phase III trials, INPULSIS 1 and 2, comparing 150 mg bid of nintedanib with placebo in 1066 patients, showed a reduction in the annual rate of decline in absolute and percent predicted FVC (primary endpoint) and an increase in time to the first acute exacerbation for nintedanib.²⁶ With these results, the EMA few months after the FDA approved nintedanib for the treatment of IPF in January 2015.

A new era emerged for patients with IPF following the INPULSIS²⁶ and ASCEND²⁵ trials and the approval of nintedanib and pirfenidone.²⁹ The two drugs were identified in national and international guidelines on the diagnosis and treatment of IPF as being efficacious in slowing functional decline and disease progression in IPF patients.^{1,30-33}

The nintedanib and pirfenidone trials showed similar efficacy results but raised logical questions related to how the drugs would perform in the real world, outside the restrictions of the trials. The inclusion criteria varied somewhat between the INPULSIS (nintedanib) and ASCEND (pirfenidone) trials. The pirfenidone trials^{21,25} included patients with percent predicted FVC 50–90%, predicted DLCO 30–90% and high-resolution computed tomography (HRCT) images indicating either definite or possible UIP, however with confirmation by surgical lung biopsy. The nintedanib trials,^{26,28} by contrast, included patients with percent predicted FVC $>50\%$, predicted DLCO 30–79%, and HRCT images indicating definite or possible UIP. Following publication of the trials, several post-marketing surveillance studies and subgroup analyses investigating effects according to age or stage of disease were undertaken in order to answer several questions: If these drugs are efficacious in slowing the progression of IPF, should they be used earlier? How will they behave in patients with more severe disease? Will their effects extend beyond the trial period?^{29,34}

When should IPF treatment be started?

The most controversial question currently surrounding IPF treatment is probably when it should be started. We know that IPF is a progressive disease and that both pirfenidone and nintedanib slow functional decline. However, some patients remain stable for several months and it has been argued that in a stable patient with mild disease, treatment should be postponed until functional decline begins. Nevertheless, it is impossible to predict the rate or severity of disease progression in each patient or to know when they will experience an acute exacerbation. Moreover, we cannot be sure that deleterious subclinical changes are not taking place in patients without signs of significant functional deterioration.

In a recent post hoc subgroup analysis of pooled data from the INPULSIS trials, Kolb et al. described similar rates of FVC decline in nintedanib-treated patients with percent predicted FVC $>90\%$ and $\leq 90\%$ (Fig. 1).³⁵ Other pre-specified subgroup analyses have shown similar results, with a consistent effect observed for nintedanib in patients with FVC $\leq 70\%$ and $>70\%$.³⁶

In a post hoc analysis of pooled data from the CAPACITY and ASCEND trials, Albera et al.³⁷ showed similar clinically significant disease progression (decline in FVC, 6MWD, and dyspnea measured by the University of California, San Diego Shortness of Breath Questionnaire) at 12 months in pirfenidone-treated patients with more preserved lung function (FVC $\geq 80\%$ or GAP stage I) and less preserved lung function (FVC $<80\%$ or GAP stage II–III) at baseline. The GAP index is a multidimensional IPF staging model that takes into account gender (G), age (A), and 2 lung physiology variables (P) (FVC and DLCO); it distinguishes between stages I, II, and III.³⁸ The magnitude of the pirfenidone treatment




Figure 1 Evidence that favors the use of antifibrotics in IPF patients with early disease. (A) Nintedanib (adapted from 35), (B) Pirfenidone (adapted from 37).

effect was comparable between the subgroups, regardless of whether lung function was classified as using FVC or the GAP model (Fig. 1).³⁷

The above data suggest that patients diagnosed in early stages of disease experience significant functional deterioration and that both nintedanib and pirfenidone have a positive effect in terms of slowing progression in these early stages (Fig. 2), clearly supporting the recommendation to initiate treatment immediately after IPF diagnosis and highlighting the importance of prompt diagnosis.

Severe disease

Percent predicted FVC <50% is usually associated with severe disease. As stated earlier, this was an exclusion criterion in both the pirfenidone and nintedanib trials.^{21,25,26,28} Information about the potential effects of antifibrotic agents in patients with severe disease is thus scarce, and overall, the treatment indications outlined by the health authorities exclude patients with this grade of functional impairment.

Some interesting data in this respect, however, have emerged from post-marketing surveillance studies. In the open-label INPULSIS-ON extension trial, patients who started treatment with nintedanib 150 mg bid with percent predicted FVC ≤50% (n = 24) showed a similar absolute




Figure 2 Schematic synthesis of the level of evidence of antifibrotic use in different IPF patient subgroups.

mean change in FVC from baseline to week 48 as those with FVC >50% at baseline (-62.3 mL vs. -87.9 mL),³⁹ suggesting that nintedanib may have a similar therapeutic effect in advanced forms of the disease.

In a real-life retrospective study of pirfenidone in several Italian interstitial lung disease centers, Harari et al.⁴⁰

evaluated 128 IPF patients stratified according to FVC and GAP stage, and reported a greater reduction in decline in percent predicted FVC in patients with moderate to severe disease.

In Japan, a retrospective evaluation of 1371 patients who began pirfenidone in the first year after its approval for IPF treatment detected functional and symptomatic stabilization, regardless of degree of functional impairment.⁴¹ Two-thirds of the patients were considered to have advanced disease (stage III–IV, according to a four-stage Japanese IPF staging model based on partial pressure of arterial oxygen at rest and SpO₂ during the 6 MW test).⁴¹

At the recent 2016 European Respiratory Congress, Costabel and colleagues⁴² reported on the results of a comparison of 54 patients with percent predicted FVC $\leq 50\%$ with 530 patients with FVC $>50\%$ in the RECAP trial, which was an extension of the CAPACITY trials. Although a higher treatment discontinuation rate was observed in the subgroup with more advanced disease, long-term treatment with pirfenidone resulted in a similar rate of FVC decline in both groups.

Despite the relatively small number of patients, the above data suggest that both nintedanib and pirfenidone have a positive effect in patients who have advanced disease at diagnosis (Fig. 2).

Is the treatment effect maintained after 52 weeks?

Another question that post-marketing surveillance studies and extension trials such as RECAP⁴³ and INPULSIS-ON^{44,45} have attempted to answer is whether or not the positive effect observed for nintedanib and pirfenidone in terms of slowing FVC decline is maintained after 52 weeks.

In 2014, Valeyre et al.⁴⁶ published the results of a long-term safety assessment of patients treated with pirfenidone in the CAPACITY trials. Although safety was the primary focus of the study, the authors demonstrated that treatment with pirfenidone for up to 7.7 years (median, 2.6 years; range, 1 week–7.7 years) was not only well tolerated but also showed a persistent positive therapeutic effect.⁴⁶

More recently, in an oral communication at the 2016 ERS Congress (London, 3–9 September 2016), Noble et al.⁴⁷ presented data from the RECAP extension study on the long-term effects of pirfenidone on percent predicted FVC and showed that the drug maintained its effect over more than 3 years.

Finally, in a recent presentation of results from the INPULSIS-ON extension study, Crestani showed that FVC decline was similar to that observed in the original INPULSIS trials, suggesting that like pirfenidone, nintedanib also maintained its effect for over 3 years.^{44,45}

What should be done once disease progression is confirmed?

Disease progression in IPF is defined as a sustained decline of more than 10% in FVC and/or of 15% in DLCO. Lung function is usually evaluated every 6 months following initiation of treatment. Once disease progression has been established,

the treating physician(s) can choose to suspend the drug and administer palliative care only; suspend the drug and switch to an alternative therapy; add an alternative therapy; or continue the drug despite the functional decline. There is insufficient evidence, however, to support any of these options. In May 2016, Nathan et al.⁴⁸ published the results of a pooled analysis of patients from the CAPACITY and ASCEND trials showing that in the subgroup of patients who experienced a functional decline in FVC $>10\%$ after 6 months, those who continued to receive pirfenidone had a lower risk of subsequent FVC decline or death. These results suggest that maintaining antifibrotic therapy may confer benefits even after disease progression is confirmed.

Bonella et al.,⁴⁹ in a German multicenter observational study of nintedanib in IPF, reported that a subgroup of patients who had shown disease progression under pirfenidone, achieved clinical and functional stability when switched to nintedanib. A combination regimen of pirfenidone and nintedanib has also been proposed, as theoretically it would allow synergistic activity in different fibrotic pathways. One safety and pharmacokinetics study reported acceptable tolerability for nintedanib administered alone or with pirfenidone and also showed that nintedanib bioavailability may decrease with the co-administration of pirfenidone.⁵⁰ Despite these findings, more data and studies are needed to guide treatment strategies in patients with disease progression.

What is the impact of adverse events induced by nintedanib or pirfenidone?

The most common adverse events reported for nintedanib in the TOMORROW²⁸ and INPULSIS trials²⁶ were diarrhea, nausea, and vomiting, which were more prevalent in the 150 mg dose group. Although 60% of patients in the INPULSIS trials developed diarrhea, only 4% discontinued treatment for this reason. In a pooled analysis from the TOMORROW and INPULSIS trials, Richeldi et al.⁵¹ found that 20.6% of patients in the nintedanib group prematurely discontinued treatment due to overall adverse events versus 15.0% in the placebo group. Nearly 30% of patients in both groups experienced one or more serious adverse events. Adverse events due to nintedanib, however, are usually mild or moderate and can be easily managed in most patients.

An interim safety analysis of the INPULSIS-ON extension study^{44,45} showed that patients who completed 96 weeks of nintedanib treatment experienced fewer adverse events (316.8 events per 100 patient-years) than those who completed the initial 52-week evaluation (632.6 events) and those who initiated treatment after 52 weeks on placebo (550.6 events). A similar situation was observed for serious adverse events (33.9 vs. 36.7 and 38.3 events per 100 patient-years) and events leading to treatment discontinuation (14.6 vs. 21.4 events per 100 patient-years in the other two groups). The author concluded that these interim results from the INPULSIS-ON trial support the long-term efficacy and safety of nintedanib in patients with IPF.

The most common adverse events during the pirfenidone CAPACITY¹⁹ and ASCEND trials²⁵ were gastrointestinal events (nausea, dyspepsia, vomiting, and anorexia) and skin

disorders (rash, photosensitivity). The events were generally mild or moderate, reversible with dose reductions, and without clinically significant consequences.

In a comprehensive analysis of safety across four clinical trials evaluating pirfenidone in patients with IPF, the more frequent adverse events reported were also mild to moderate nausea (40%), dyspepsia (21%), vomiting (18%), and rash (26%). These events rarely led to treatment discontinuation, despite the longer median duration of exposure to pirfenidone (2.6 years).⁴⁶ This study also showed that while gastrointestinal and skin-related adverse events are relatively common at the beginning of treatment, they decrease considerably after the first 6 months and remain low during the course of treatment.

Ogura et al.,⁴¹ in a prospective post-marketing surveillance study of patients with IPF administered pirfenidone in the first year after its launch in Japan, found a similar safety profile to that reported in the Japanese phase II and III trials, with 64.6% of patients experiencing at least one adverse event. The most common events were decreased appetite, photosensitivity, and nausea, and these resolved or improved in the majority of cases.

The results of the RECAP open-label extension study of pirfenidone showed that the type and frequency of adverse events after 60 weeks of treatment were similar to those observed in the initial 72-week phase III CAPACITY trials and rarely resulted in early discontinuation of therapy.⁴³ The incidence of nausea and photosensitivity was 35.4% and 11.9% in the CAPACITY trials versus 32.0% and 11.8% in the RECAP study. Rash and diarrhea, by contrast, were less common in RECAP (18.0% and 16.9% vs. 31.0% and 27.0%, respectively).^{21,43}

Conclusions

Based on the available data from clinical trials and extension studies, we can conclude that both pirfenidone and nintedanib have a significant effect on FVC decline, regardless of disease stage assessed by FVC or GAP. Moreover, the RECAP and INPULSIS-ON extension trials showed that the effect was maintained over time. Both nintedanib and pirfenidone were found to prolong survival, with a reduction in both IPF-related and all-cause mortality.

Despite the relatively high rates of adverse events, which are mostly gastrointestinal in nature, the existing data support the recommendation that treatment with nintedanib or pirfenidone should be considered when IPF is diagnosed, regardless of disease stage. Since IPF is a progressive lung disease, early diagnosis and treatment are crucial for slowing functional decline, reducing symptoms, and improving quality of life.

Ethical disclosures

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this study.

Confidentiality of data. The authors declare that no patient data appear in this article.

Right to privacy and informed consent. The authors declare that no patient data appear in this article.

Conflicts of interest

The authors have no conflicts of interest to declare.

References

- Robalo Cordeiro C, Campos P, Carvalho L, Campinha S, Clemente S, Figueiredo L, et al. Consensus document for the diagnosis and treatment of idiopathic pulmonary fibrosis: Joint Consensus of Sociedade Portuguesa de Pneumologia Sociedade Portuguesa de Radiologia e Medicina Nuclear e Sociedade Portuguesa de Anatomia Patológica. *Rev Port Pneumol.* 2016;22:112–22.
- Poletti V, Ravaglia C, Buccioli M, Tantalocco P, Piciucchi S, Dubini A, et al. Idiopathic pulmonary fibrosis: diagnosis and prognostic evaluation. *Respiration.* 2013;86:5–12.
- King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. *Lancet.* 2011;378:1949–61.
- Tzouveleakis A, Bonella F, Spagnolo P. Update on therapeutic management of idiopathic pulmonary fibrosis. *Ther Clin Risk Manag.* 2015;11:359–70.
- Behr J. Approach to the diagnosis of interstitial lung disease. *Clin Chest Med.* 2012;33:1–10.
- Ryu JH, Daniels CE, Hartman TE, Yi ES. Diagnosis of interstitial lung diseases. *Mayo Clin Proc.* 2007;82:976–86.
- Meyer KC. Diagnosis and management of interstitial lung disease. *Transl Respir Med.* 2014;2:4.
- Cottin V, Richeldi L. Neglected evidence in idiopathic pulmonary fibrosis and the importance of early diagnosis and treatment. *Eur Respir Rev.* 2014;23:106–10.
- American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). *Am J Respir Crit Care Med.* 2000;161:646–64.
- King CS, Nathan SD. Practical considerations in the pharmacologic treatment of idiopathic pulmonary fibrosis. *Curr Opin Pulm Med.* 2015;21:479–89.
- Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. *N Engl J Med.* 2012;366:1968–77.
- King TE Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. *Lancet.* 2009;374:222–8.
- Günther A, Korfei M, Mahavadi P, von der Beck D, Ruppert C, Markart P. Unravelling the progressive pathophysiology of idiopathic pulmonary fibrosis. *Eur Respir Rev.* 2012;21:152–60.
- Selman M, King TE, Pardo A, American Thoracic Society, European Respiratory Society, American College of Chest Physicians. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. *Ann Intern Med.* 2001;134:136–51.
- Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. *Am J Respir Crit Care Med.* 2011;183:788–824.
- Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. *N Engl J Med.* 2005;353:2229–42.
- Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, et al. Double-blind, placebo-controlled trial of pirfenidone in patients

- with idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med.* 2005;171:1040–7.
18. Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, et al. Pirfenidone in idiopathic pulmonary fibrosis. *Eur Respir J.* 2010;35:821–9.
 19. Kim ES, Keating GM. Pirfenidone: a review of its use in idiopathic pulmonary fibrosis. *Drugs.* 2015;75:219–30.
 20. Takeda Y, Tsujino K, Kijima T, Kumanogoh A. Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis. *Patient Prefer Adherence.* 2014;8:361–70.
 21. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. *Lancet.* 2011;377:1760–9.
 22. Idiopathic Pulmonary Fibrosis Clinical Research Network, Martinez FJ, de Andrade JA, Anstrom KJ, King TE Jr, Raghu G. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. *N Engl J Med.* 2014;370:2093–101.
 23. Oldham JM, Ma SF, Martinez FJ, Anstrom KJ, Raghu G, Schwartz DA, et al. TOLLIP MUC5B, and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med.* 2015;192:1475–82.
 24. Homma S, Azuma A, Taniguchi H, Ogura T, Mochiduki Y, Sugiyama Y, et al. Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis. *Respirology.* 2012;17:467–77.
 25. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. *N Engl J Med.* 2014;370:2083–92.
 26. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. *N Engl J Med.* 2014;370:2071–82.
 27. Wollin L, Wex E, Pautsch A, Schnapp G, Hostettler KE, Stowasser S, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. *Eur Respir J.* 2015;45:1434–45.
 28. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. *N Engl J Med.* 2011;365:1079–87.
 29. Hunninghake GM. A new hope for idiopathic pulmonary fibrosis. *N Engl J Med.* 2014;370:2142–3.
 30. Xaubet A, Ancochea J, Bollo E, Fernández-Fabrellas E, Franquet T, Molina-Molina M, et al. Sociedad Española de Neumología y Cirugía Torácica (SEPAR) Research Group on Diffuse Pulmonary Diseases Guidelines for the diagnosis and treatment of idiopathic pulmonary fibrosis. Sociedad Española de Neumología y Cirugía Torácica (SEPAR) Research Group on Diffuse Pulmonary Diseases. *Arch Bronconeumol.* 2013;49:343–53.
 31. Raghu G, Rochwerf B, Zhang M, Garcia CA, Azuma A, Behr J, et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. *Am J Respir Crit Care Med.* 2015;192:e3–19.
 32. Cottin V, Crestani B, Valeyre D, Wallaert B, Cadranet J, Dalphin JC, et al. Diagnosis and management of idiopathic pulmonary fibrosis: French practical guidelines. *Eur Respir Rev.* 2014;23:193–214.
 33. Puglisi S, Torrisi SE, Vindigni V, Giuliano R, Palmucci S, Mulè M, et al. New perspectives on management of idiopathic pulmonary fibrosis. *Ther Adv Chronic Dis.* 2016;7:108–20.
 34. Hughes G, Toellner H, Morris H, Leonard C, Chaudhuri N. Real World Experiences: pirfenidone and nintedanib are effective and well tolerated treatments for idiopathic pulmonary fibrosis. *J Clin Med.* 2016;5, pii:E78.
 35. Kolb M, Richeldi L, Behr J, Maher TM, Tang W, Stowasser S, et al. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. *Thorax.* 2016, pii: thoraxjnl-2016-102087.
 36. Costabel U, Inoue Y, Richeldi L, Collard HR, Tschöepe I, Stowasser S, et al. Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. *Am J Respir Crit Care Med.* 2016;193:178–85.
 37. Albera C, Costabel U, Fagan EA, Glassberg MK, Gorina E, Lancaster L, et al. Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. *Eur Respir J.* 2016;48:843–51.
 38. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. *Ann Intern Med.* 2012;156:684–91.
 39. Wuys WA, Kolb M, Stowasser S, Stansen W, Huggins JT, Raghu G. First data on efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis and forced vital capacity of $\leq 50\%$ of predicted value. *Lung.* 2016;194:739–43.
 40. Harari S, Caminati A, Albera C, Vancheri C, Poletti V, Pesci A, et al. Efficacy of pirfenidone for idiopathic pulmonary fibrosis: an Italian real life study. *Respir Med.* 2015;109:904–13.
 41. Ogura T, Azuma A, Inoue Y, Taniguchi H, Chida K, Bando M, et al. All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis. *Respir Invest.* 2015;53:232–41.
 42. Costabel U, Albera C, Kirchgäessler K, Gilberg F, Petzinger U, Noble P. Analysis of patients with idiopathic pulmonary fibrosis (IPF) with percent predicted forced vital capacity (FVC) $< 50\%$ treated with pirfenidone (PFD) in RECAP. *Eur Respir J.* 2016;48 suppl 60:OA1813.
 43. Costabel U, Albera C, Bradford WZ, Hormel P, King TE Jr, Noble PW, et al. Analysis of lung function and survival in RECAP: an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis. *Sarcoidosis Vasc Diffuse Lung Dis.* 2014;31:198–205.
 44. Crestani B, Ogura T, Pelling K, Coeck C, Quaresma M, Kreuter M, et al. Interim analysis of nintedanib in an open-label extension of the INPULSIS[®] trials (INPULSIS[®]-ON). *Eur Respir J.* 2015;46 suppl 59:OA4495.
 45. Crestani B, Quaresma M, Kaye M, Stansen W, Stowasser S, Kreuter M. Long-term treatment with nintedanib in patients with IPF: an update from INPULSIS[®]-ON. *Eur Respir J.* 2015;48 suppl 60:OA4960.
 46. Valeyre D, Albera C, Bradford WZ, Costabel U, King TE Jr, Leff JA, et al. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. *Respirology.* 2014;19:740–7.
 47. Noble P, Albera C, Kirchgäessler K, Gilberg F, Petzinger U, Costabel U. Long-term effectiveness of pirfenidone in patients with idiopathic pulmonary fibrosis is independent of baseline forced vital capacity. *Chest.* 2016;150:538A.
 48. Nathan SD, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, et al. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. *Thorax.* 2016;71:429–35.
 49. Bonella F, Kreuter M, Hagemeyer L, Neurohr C, Keller C, Kohlhaeufel MJ, et al. Insights from the German compassionate use program of nintedanib for the treatment of idiopathic pulmonary fibrosis. *Respiration.* 2016;92:98–106.
 50. Ogura T, Taniguchi H, Azuma A, Inoue Y, Kondoh Y, Hasegawa Y, et al. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. *Eur Respir J.* 2015;45:1382–92.
 51. Richeldi L, Cottin V, du Bois RM, Selman M, Kimura T, Bailes Z, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS[®] trials. *Respir Med.* 2016;113:74–9.